BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 16635597)

  • 1. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
    Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
    Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
    Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
    Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of tissue plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen with coronary artery disease in South Indian male subjects.
    Deepa R; Velmurugan K; Saravanan G; Dwarakanath V; Agarwal S; Mohan V
    J Assoc Physicians India; 2002 Jul; 50():901-6. PubMed ID: 12126344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
    Sebestjen M; Zegura B; Guzic-Salobir B; Keber I
    Wien Klin Wochenschr; 2001 Feb; 113(3-4):113-8. PubMed ID: 11253736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction--the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction.
    Scarabin PY; Aillaud MF; Amouyel P; Evans A; Luc G; Ferrières J; Arveiler D; Juhan-Vague I
    Thromb Haemost; 1998 Nov; 80(5):749-56. PubMed ID: 9843166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex differences in the determinants of fibrinolytic activity.
    MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ
    Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
    Kvasnicka J; Skrha J; Perusicová J; Maslowská H; Pochopová L
    Cas Lek Cesk; 1996 Mar; 135(6):174-7. PubMed ID: 8681360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].
    Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P
    Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
    Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
    Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy.
    Brazionis L; Rowley K; Jenkins A; Itsiopoulos C; O'Dea K
    Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):786-91. PubMed ID: 18239151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system.
    Sills ES; Drews CD; Perloe M; Tucker MJ; Kaplan CR; Palermo GD
    Gynecol Endocrinol; 2003 Jun; 17(3):231-7. PubMed ID: 12857431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent relation of vital exhaustion and inflammation to fibrinolysis in apparently healthy subjects.
    von Känel R; Frey K; Fischer J
    Scand Cardiovasc J; 2004 Mar; 38(1):28-32. PubMed ID: 15204244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
    Kockx M; de Maat MP; Knipscheer HC; Kastelein JJ; Kluft C; Princen HM; Kooistra T
    Thromb Haemost; 1997 Oct; 78(4):1167-72. PubMed ID: 9364979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction.
    Rallidis LS; Megalou AA; Papageorgakis NH; Trikas AG; Chatzidimitriou GI; Tsitouris GK
    Thromb Haemost; 1996 Sep; 76(3):417-21. PubMed ID: 8883280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy.
    Hamsten A; Syvänne M; Silveira A; Luong LA; Nieminen MS; Humphries S; Frick MH; Taskinen MR
    Thromb Haemost; 2000 Mar; 83(3):397-403. PubMed ID: 10744143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
    Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High intakes of trans monounsaturated fatty acids taken for 2 weeks do not influence procoagulant and fibrinolytic risk markers for CHD in young healthy men.
    Sanders TA; Oakley FR; Crook D; Cooper JA; Miller GJ
    Br J Nutr; 2003 Jun; 89(6):767-76. PubMed ID: 12828793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.